Treatment and survival of patients diagnosed with high-risk HR+/HER2- breast cancer in the Netherlands:a population-based retrospective cohort study
BACKGROUND: Several factors may increase the risk of recurrence of patients diagnosed with hormone receptor-positive human epidermal growth factor receptor 2-negative (HR+/HER2-) breast cancer (BC). We aim to determine the proportion of patients with high-risk HR+/HER2- BC within the total HR+/HER2- BC cohort and compare their systemic treatments and survival rates with those of patients with low- and intermediate-risk HR+/HER2- BC and triple-negative (TN) BC. PATIENTS AND METHODS: Women diagnosed with nonmetastatic invasive HR+/HER2- BC and TNBC in the Netherlands between 2011 and 2019 were i... Mehr ...
Verfasser: | |
---|---|
Dokumenttyp: | Artikel |
Erscheinungsdatum: | 2024 |
Reihe/Periodikum: | Lammers , S W M , Meegdes , M , Vriens , I J H , Voogd , A C , de Munck , L , van Nijnatten , T J A , Keymeulen , K B M I , Tjan-Heijnen , V C G & Geurts , S M E 2024 , ' Treatment and survival of patients diagnosed with high-risk HR+/HER2- breast cancer in the Netherlands : a population-based retrospective cohort study ' , ESMO Open , vol. 9 , no. 5 , 103008 . https://doi.org/10.1016/j.esmoop.2024.103008 |
Schlagwörter: | breast neoplasms / hormone receptor-positive / prognosis / registries / survival |
Sprache: | Englisch |
Permalink: | https://search.fid-benelux.de/Record/base-27597454 |
Datenquelle: | BASE; Originalkatalog |
Powered By: | BASE |
Link(s) : | https://cris.maastrichtuniversity.nl/en/publications/bce0ac5b-d107-49c3-bd16-c8b1a4763997 |